Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2022 | Story Prof Felicity Burt, Prof Dominique Goedhals and Dr Charles Kotzé
Prof Felicity Burt, Dr Charles Kotze and Prof Dominique Goedhals
From the left; Prof Felicity Burt, Dr Charles Kotzé and Prof Dominique Goedhals.

Opinion article by Prof Felicity Burt , Prof Dominique Goedhals , Division of Virology at the University of the Free State (UFS), and Dr Charles Kotzé, National Health Laboratory Service (NHLS), Universitas Academic Hospital.
The recent COVID-19 pandemic has certainly highlighted the importance of vigilance and awareness of emerging diseases with public health implications. The monkeypox virus has recently made headlines, after the detection of more than 200 cases in geographically distinct regions. On 13 May, the World Health Organisation (WHO) was notified of human cases of the monkeypox disease occurring in the United Kingdom, outside of the known endemic region.

Exported cases have been detected previously and usually occur sporadically. In contrast, within the past two weeks, human cases have been confirmed in at least 21 countries, including various European countries, the United Kingdom, Israel, the Canary Islands, Canada and the United States, and Australia. The initial case appears to have been a traveller from Nigeria. Sequence data may help to determine if there have been multiple exportations from West Africa. 

What is monkeypox and what do we know

What is monkeypox and what do we know about the aetiologic agent? Monkeypox is the name given to a disease caused by the monkeypox virus, a zoonotic pathogen endemic in Central and West Africa and responsible for cases of the disease in the endemic region, with occasional exported cases in travellers. The virus was initially identified in 1958 in monkeys housed at a research laboratory in Denmark, and the name monkeypox was derived from the appearance of lesions and the occurrence in monkeys. The first human case was identified 52 years ago in the Democratic Republic of the Congo. Since then, human monkeypox cases have been reported in several other Central and West African countries: Cameroon, the Central African Republic, Ivory Coast, the Democratic Republic of the Congo, Gabon, Liberia, Nigeria, Republic of the Congo, and Sierra Leone. The first monkeypox outbreak outside of Africa was in the United States of America in 2003 and was linked to contact with infected prairie dogs imported as exotic pets. Since then, there have been various small, contained outbreaks outside of Africa that have mostly been linked to the importation of the virus from African countries. 

The virus is related to the smallpox virus, which was eradicated in the 1970s by vaccination. Although belonging to the same family of viruses as the smallpox virus, the disease caused by monkeypox is less severe, with fewer fatalities.   Unlike smallpox, which carries a case fatality rate of 30%, the case fatality rate in monkeypox is low (estimated at 3-6% in more recent outbreaks).  There are two clades of the monkeypox virus: the West African clade and the Congo Basin (Central African) clade. In this outbreak, all of the cases have been linked to the West African clade of the monkeypox virus.

Transmission occurs from animal to human, and from human to human, through close contact with lesions, body fluids, and contaminated materials. The virus enters the body through the respiratory tract, mucous membranes, or broken skin.  The disease begins with non-specific symptoms such as fever, headache, muscle pains, and swollen lymph nodes. This is followed by the typical skin rash, which progresses through stages known as macules, then papules, vesicles, pustules, and lastly crusts or scabs. Lesions can also occur on mucous membranes such as the mouth, eye, and genital area.  The infectious period lasts through all stages of the rash, until all the scabs have fallen off. There are a number of other infectious and non-infectious conditions that need to be differentiated; therefore, individuals presenting with these symptoms will need to consult their doctor to determine whether a diagnosis of monkeypox needs to be considered. In the current outbreak, a number of the cases in the United Kingdom and Europe have been detected in men who have sex with men, during visits to sexual health clinics. This pattern of spread has not previously been described and it remains to be determined whether the spread has occurred through close person-to-person contact or through sexual transmission.  

Vaccination against smallpox virus offers 85% protection against monkeypox

To date, no cases have been detected in South Africa, but the recent global spread of the severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2) highlights the ability of pathogens to spread. The National Institute for Communicable Diseases (NICD) in Johannesburg offers a specialised diagnostic service for the monkeypox virus, using molecular assays and electron microscopy. 

Vaccination against the smallpox virus is believed to offer 85% protection against monkeypox, hence older persons should have some protection; however, vaccination against smallpox was phased out globally following the eradication of smallpox during the 1970s. A more recently developed vaccine against monkeypox is available but has very limited availability.  No specific antivirals are available with proven efficacy in clinical trials.

While the monkeypox virus can be spread via the respiratory route, this occurs in the form of large droplets, rather than aerosol transmission, which is seen with SARS-CoV-2 (causing COVID-19). Aerosols are smaller particles that can remain suspended in the air for prolonged periods, facilitating the transmission of SARS-CoV-2. Monkeypox is therefore less contagious than COVID-19, as close contact is required for longer periods.  For this reason, many experts around the world predict that this outbreak will not spread like SARS-CoV-2. The importation of monkeypox to South Africa is a definite possibility, because South Africa is a significant economic and travel hub for Africa. Previous outbreaks of monkeypox in non-endemic areas have been interrupted by contact tracing and isolation, which was very effective in controlling further spread.  Heightened vigilance is therefore needed for the early detection of such cases.

News Archive

Prof Hendrik Swart richly contributes to research of phosphors
2014-12-02

Prof Hendrik Swart
Photo: Merwelene van der Merwe

Since his appointment as the South African Research Chairs Initiative (SARChI) Chair, there has been a sharp increase in the number of papers and publications by Prof Hendrik Swart, Senior Professor in the Department of Physics at the University of the Free State (UFS). From January this year, he has already published 78 articles. Some of the journals that has published his work, includes:

• Nanotechnology (impact of 3.67)
• Dalton Transactions (impact of 4.097)
• Sensors and Actuators B: Chemical (impact 3.84)

“My biggest success, however, is the powerful group of researchers we have built over the years. Staff, postdocs and students – without them it would have been impossible. I am therefore much indebted to my groups on both the Bloemfontein and Qwaqwa Campuses.

“The good apparatus we acquired via a sponsorship from the National Research Foundation and Sasol is also one of the main reasons for this. The financial support I get from the university’s research office is of course also a contributing factor,” he says.

For the past 20 years, Prof Swart has been conducting research on any substance that glows. “I only adjust the focus to fit in with current trends,” he says.

Prof Swart believes that his research will make a contribution to the fundamental knowledge about phosphors, as well as to the training of good students for the academic and industrial world on the outside. For the man on the street, his research translates into better, brighter lights that use less energy.

His more recent research focuses on the development of nano-phosphors for light-emitting diodes (LEDS) and organic light-emitting diodes (OLED).

Prof Swart has presented papers on his research not only nationally, but all over the world – including countries in Europe and the East. Some of the most recent papers presented by him and his colleagues/postgraduate students include:

• Applications of AES, XPS and TOF SIMS to phosphor materials at die 15th European Conference on Applications of Surface and Interface Analysis 2013 in Forte Village Resort, Sardinia, Italy.
• Luminescent properties of phosphor nano thin films at the first International Symposium on Nanoparticles/Nanomaterials and Applications in Caparica (Lisbon, Portugal), where he was an invited speaker.
• Role of surface and deep-level defects on the emission of nano metal oxides at the 2014 NanoAfrica international conference, Vanderbijlpark, South Africa, where he delivered the keynote address.
• PHI systems and their modifications at KOVSIES at the PHI European User Meeting in Ismaning (Munich), Germany, where he was invited to speak.

Prof Swart also delivered the keynote address at the SETCOR International Conference on Smart Materials and Surfaces in Bangkok, Thailand. His lecture was titled, ‘Role of surface and deep-level defects on the emission and degradation of phosphor materials’.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept